lung cancer gene and literature database Home
Cancer metastasis database

Annotation category 5

Literatures

Literature evidence

Links to all GeneRIF Items

94025

PubMed (Gene Name)

Literature evidence

17413979 (MUC16)

Our results suggest that an immunohistochemical panel consisting of TTF-1, CEA, CA-125, and OCT-4 is helpful in distinguishing most pulmonary and ovarian carcinomas with clear cell features.

19383238 (MUC16)

The utility of the tumour markers carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 19-9, carbohydrate antigen 15-3, alpha-fetoprotein and human chorionic gonadotropin for the diagnosis solitary pulmonary nodules, was investigated.

22674301 (MUC16)

Data show that the prognostic values of CA125, CA19.9, neuron-speci fi c enolase (NSE), and squamous cell carcinoma antigen (SCC) for stage I non-small-cell lung cancer NSCLC are limited.

23712355 (MUC16)

High levels of neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125) and squamous cell carcinoma antigen (SCC) were detected in 306 (63.6%), 89 (18.5%) and 125 (26.0%) non-small cell lung cancer patients, respectively.

24913812 (MUC16)

The elevation of CA125 before treatment predicts a poor prognosis in patients with multiple brain metastases from non-small cell lung cancer before and after treatment of whole-brain radiotherapy.

26163610 (MUC16)

Elevation of serum CA125 is associated with Non-small Cell lung cancer.

26560853 (MUC16)

CEA, NSE, CA125 and pro-GRP could serve as biomarkers for SCLC, and CEA and CYFRA21-1 could serve as biomarkers for NSCLC. Pro-GRP, CA125 and CEA were related to the clinical stages of lung cancer

27002010 (MUC16)

Serum CA 12-5 level and TNM status predict the long-term prognosis of resected primary adenosquamous carcinoma of the lung.

29797475 (MUC16)

Studied levels of mucin 16 (CA125), adenosine deaminase and midkine as tumor markers in nonsmall cell lung cancer-associated malignant pleural effusion.

30672447 (MUC16)

The significance of combined serum CEA and CA125 detection in lung cancer is confirmed.

30790454 (MUC16)

These results provide a potential, novel biomarker for lung cancer progression, in particular, protease resistant MUC16 peptides; and suggest a possible mechanism of immune escape entailing the reduction of mutant peptides available for HLA class I binding.

33056994 (MUC16)

ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells.

33382999 (MUC16)

cancer antigen-125 is a predictor of mortality in patients with pulmonary arterial hypertension.